Latest Headlines

PR Newswire

Clywedog Therapeutics Announces Activation of All Centers and Patient Dosing in Multicenter, International Phase 1b Clinical Study of Balomenib in Type 2 Diabetes

PR Newswire

Federal Data Show Encouraging Youth Substance Use Trends, While Underscoring Need for Continued Progress and Action in Areas of Concern

PR Newswire

PRMB Investor Alert: Hagens Berman Scrutinizing Alleged Undisclosed Technology Failures and Supply Chain Risks in Pending Primo Brands (PRMB) Lawsuit